English
Back
Download
Log in to access Online Inquiry
Back to the Top

NEWS

Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva® Smart GLP-1™ Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)

Thursday, 12th December at 7:00 am
RJVA-001 was successfully delivered in large animal Yucatan pig models at low total viral dose

Results confirm ability to directly target pancreas with novel delivery catheter and route of administration

Local delivery of RJVA-001 achieved therapeutically relevant GLP-1 expression within pancreatic beta cells with no adverse safety effects observed

Company plans to initiate first-in-human studies with RJVA-001 in first half of 2025
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
Translate
Report
2479 Views
Comment
Sign in to post a comment
    Spread kindness and love. Life is short. Don’t let greed eat you.
    8816
    Followers
    53
    Following
    103K
    Visitors
    Follow